References
- Mombaerts I, Schlingemann RO, Goldschmeding R, Koornneef L. Are systemic corticosteroids useful in the management of orbital pseudotumors? Ophthalmology. 1996;103(3):521–528. doi:https://doi.org/10.1016/S0161-6420(96)30663-5.
- Yuen SJA, Rubin PAD. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003;121(4):491–499. doi:https://doi.org/10.1001/archopht.121.4.491.
- Stanbury RM, Graham EM. Systemic corticosteroid therapy—side effects and their management. Br J Ophthalmol. 1998;82(6):704–708. doi:https://doi.org/10.1136/bjo.82.6.704.
- Ho VH, Chevez‐Barrios P, Jorgensen JL, Silkis RZ, Esmaeli B. Receptor expression in orbital inflammatory syndromes and implications for targeted therapy. Tissue Antigens. 2007;70(2):105–109. doi:https://doi.org/10.1111/j.1399-0039.2007.00863.x.
- Abell RG, Patrick A, Rooney KG, McKelvie PA, McNab AA. Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab. Ocul Immunol Inflamm. 2015;23(2):176–179. doi:https://doi.org/10.3109/09273948.2013.863943.
- Vrcek I, Wotipka E, Somogyi M, Nakra T. Rapid and complete vision loss due to idiopathic orbital inflammation with partial recovery following orbital decompression. Bayl Univ Med Cent Proc. 2018;31(3):372–374. doi:https://doi.org/10.1080/08998280.2018.1463043.
- Schafranski MD. Idiopathic orbital inflammatory disease successfully treated with rituximab. Clin Rheumatol. 2009;28(2):225–226. doi:https://doi.org/10.1007/s10067-008-1040-8.
- Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, et al. Rituximab therapy for refractory orbital inflammation: results of a phase I/II dose-ranging randomized clinical trial. JAMA Ophthalmol. 2014;132(5):572–578. doi:https://doi.org/10.1001/jamaophthalmol.2013.8179.
- Shao EH, Karydis A, Gemenetzi M, Taylor SRJ. Successful corticosteroid-sparing effect of rituximab in the treatment of refractory idiopathic orbital inflammatory disease. Case Rep Ophthalmol. 2013;4(3):216–218. doi:https://doi.org/10.1159/000356523.
- Kurz PA, Suhler EB, Choi D, Rosenbaum JT. Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol. 2009;93(4):546–548. doi:https://doi.org/10.1136/bjo.2007.133173.
- On AV, Hirschbein MJ, Williams HJ, Karesh JW. CyberKnife radiosurgery and rituximab in the successful management of sclerosing idiopathic orbital inflammatory disease. Ophthal Plast Reconstr Surg. 2006;22(5):395–397. doi:https://doi.org/10.1097/01.iop.0000231549.24125.7a.
- Miller CG, Barsegian A, Shinder R. Idiopathic dacryoadenitis treated with intralesional rituximab | IOVS | ARVO Journals. https://iovs-arvojournals-org.proxy.lib.umich.edu/article.aspx?articleid=2693629. Accessed June 19, 2019
- Ibrahim I, Barton A, Ibrahim A, Ho P. Idiopathic orbital inflammation successfully treated using rituximab in a patient with rheumatoid arthritis. J Rheumatol. 2012;39(9):1907. doi:https://doi.org/10.3899/jrheum.111230.C1.
- Kasi SK, Kim HJ, Basham RP, Cunningham ET, Sy A, Lustig L, et al. Idiopathic orbital inflammation associated with necrotizing scleritis and temporal bone inflammation. Ophthal Plast Reconstr Surg. 2016;32(4):e77–e79. doi:https://doi.org/10.1097/IOP.0000000000000251.
- Spindle J, Narang S, Purewal B, Shinder R. Atypical idiopathic orbital inflammation in a young girl. Ophthal Plast Reconstr Surg. 2013;29(3):e86–e88. doi:https://doi.org/10.1097/IOP.0b013e318275b649.
- Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–1192. doi:https://doi.org/10.1038/modpathol.2012.72.
- Savino G, Battendieri R, Siniscalco A, Mandarà E, Mulè A, Petrone G, et al. Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports. Rheumatol Int. 2015;35(1):183–188. doi:https://doi.org/10.1007/s00296-014-3054-7.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232. doi:https://doi.org/10.1056/NEJMoa0909905.
- Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol. 2004;138(6):925–930. doi:https://doi.org/10.1016/j.ajo.2004.06.077.
- Garcia-Pous M, Hernández-Garfella ML, Díaz-Llopis M. Treatment of chronic orbital myositis with daclizumab. Can J Ophthalmol. 2007;42(1):156–157. doi:https://doi.org/10.3129/can.j.ophthalmol.06-121.
- Sanz I. B cell depletion therapy in autoimmune diseases. Front Biosci. 2007;12(1):2546. doi:https://doi.org/10.2741/2254.
- Damato V, Evoli A, Efficacy IR. Safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342. doi:https://doi.org/10.1001/jamaneurol.2016.1637.
- Montante A, Bras AL, Pagnoux C, Perrodeau E, Ravaud P, Terrier B, Guillevin L, Durand-Zaleski I, French Vasculitis Study Group. Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2019;37 Suppl 117(2):137–143. Published online 2019.
- Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239–247. doi:https://doi.org/10.1016/S0140-6736(16)00380-9.
- Sakano H, Shih C-P, Jafari A, DeConde A, Harris JP. Multifocal inflammatory pseudotumor of the temporal bone, maxillary sinus, and orbit. Otol Neurotol. 2018;39(10):e1125–e1128. doi:https://doi.org/10.1097/MAO.0000000000001968.